Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Revenue (2020 - 2026)

Maxcyte has reported Revenue over the past 6 years, most recently at -$4.8 million for Q4 2025.

  • Quarterly Revenue fell 154.86% to -$4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.0 million through Dec 2025, down 36.24% year-over-year, with the annual reading at $21.0 million for FY2025, 45.75% down from the prior year.
  • Revenue was -$4.8 million for Q4 2025 at Maxcyte, down from $6.8 million in the prior quarter.
  • Over five years, Revenue peaked at $23.3 million in Q4 2022 and troughed at -$6.1 million in Q4 2023.
  • The 5-year median for Revenue is $8.3 million (2024), against an average of $7.1 million.
  • Year-over-year, Revenue surged 1171.97% in 2022 and then tumbled 154.86% in 2025.
  • A 5-year view of Revenue shows it stood at -$2.2 million in 2021, then surged by 1171.97% to $23.3 million in 2022, then plummeted by 126.33% to -$6.1 million in 2023, then skyrocketed by 241.9% to $8.7 million in 2024, then tumbled by 154.86% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Revenue are -$4.8 million (Q4 2025), $6.8 million (Q3 2025), and $8.5 million (Q2 2025).